Curative Biotechnology Inc
Curative Biotechnology Inc (CUBT): 5 pipeline candidates · 3 upcoming catalysts · 3 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
N/A
Lead: Approved
5 candidates
3 upcoming, next in ~1657d
N/A
A transparent, data-derived signal for Curative Biotechnology Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.0M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| allogeneic umbilical cord mesenchymal stem cells | Phase 1/Phase 2 |
| dificid | Approved |
| peripheral iv | Phase 1 |
| sivextro | Approved |
| zerbaxa | Approved |
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in Curative Biotechnology Inc's pipeline?
Curative Biotechnology Inc (CUBT) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Curative Biotechnology Inc's lead drug candidate?
Curative Biotechnology Inc's most advanced tracked candidate is allogeneic umbilical cord mesenchymal stem cells (Phase 1/Phase 2) for Myelodysplastic Syndromes; Osteonecrosis of Femoral Head.
What is Curative Biotechnology Inc's next catalyst?
Curative Biotechnology Inc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SIVEXTRO" — expected December 31, 2030.
What is Curative Biotechnology Inc's market capitalization?
Curative Biotechnology Inc's market capitalization is approximately $10.0M.
Who is the CEO of Curative Biotechnology Inc?
Mr. I. Richard Garr Esq., J.D. is the chief executive officer of Curative Biotechnology Inc (CUBT).
Get the full picture on Curative Biotechnology Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.